Literature DB >> 2022304

Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine.

J Dupre1, M R Jenner, J L Mahon, C Purdon, N W Rodger, C R Stiller.   

Abstract

We have studied the endocrine-metabolic status of patients in non-insulin-receiving (NIR) remission of insulin-dependent diabetes mellitus (IDDM) within 6-60 mo of diagnosis during administration of cyclosporine, in comparison with nondiabetic subjects. IDDM patients in NIR remission were recognized when target glycemic control (plasma glucose and mean capillary blood glucose levels less than 7.8 mM before meals) was maintained without administration of insulin for at least 2 wk. In so-called isoglycemic tests, 50 g glucose was administered orally, and the glycemic curve was simulated in a subsequent study by programmed intravenous infusion of glucose. Under these conditions, the subjects with diabetes exhibited obvious glucose intolerance: acute beta-cell responses to intravenous glucose were virtually absent but significant, although subnormal responses were present after oral glucose. The responses of plasma immunoreactive gastric inhibitory polypeptide to oral glucose were normal. After bolus intravenous injections of glucose, the patients with diabetes again exhibited glucose intolerance; acute responses of immunoreactive insulin (IRI) and C-peptide were present, although grossly obtunded. On intravenous infusion of arginine (30 g in 30 min), the patients with diabetes showed substantial but subnormal increases in plasma IRI and C-peptide. Intravenous infusion of arginine elicited increments of plasma immunoreactive glucagon (IRGI) in both groups, and this response was slightly exaggerated in the patients with diabetes. On ingestion of a standard mixed meal (Sustacal) delivering 600 cal, there was a modest but significantly greater increase in plasma glucose levels in the diabetic subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022304     DOI: 10.2337/diab.40.5.598

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  4 in total

Review 1.  Strategies for preventing type I diabetes mellitus.

Authors:  C F Verge; G S Eisenbarth
Journal:  West J Med       Date:  1996-03

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.

Authors:  Margaret T Behme; John Dupré; Thomas J McDonald
Journal:  BMC Endocr Disord       Date:  2003-04-10       Impact factor: 2.763

4.  Characterisation of the endocrine pancreas in type 1 diabetes: islet size is maintained but islet number is markedly reduced.

Authors:  Peter Seiron; Anna Wiberg; Enida Kuric; Lars Krogvold; Frode L Jahnsen; Knut Dahl-Jørgensen; Oskar Skog; Olle Korsgren
Journal:  J Pathol Clin Res       Date:  2019-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.